TWiV 952: Jake Scott put the ID in COVID-19

November 6, 2022

Infectious Disease physician Jake Scott joins TWiV to provide a west coast clinical perspective on the evolution of the COVID-19 pandemic with respect to the impact of vaccines, antivirals, variants of concern and mortality.

Hosts: Vincent Racaniello, Alan Dove, Rich Condit,  and Kathy Spindler

Guest: Jake Scott

Click arrow to play
Download TWiV 952 (63 MB .mp3, 104 min)
Subscribe (free): Apple PodcastsGoogle PodcastsRSSemail

Become a patron of TWiV!

Weekly Picks 1:30:22

Kathy10 moments for Jazz at Lincoln Center Orchestra Residency (Item 7) and Alan’s pick from TWiV 931 The Kissing Bug by Daisy Hernandez
Rich Wilderness Safaris Photographic Competition 2022
AlanMassachusetts Science Education Leadership Association, and the talk I gave to them last week
VincentAndrea Camillieri and his protagonist Inspector Montalbano

Listener Pick

FrankEconomics for the Future: Beyond the Superorganism
DebbyAs routine vaccination rates fall, polio survivor hopes her story reverses urgent trend

Intro music is by Ronald Jenkees

Send your virology questions and comments to

Leave a Reply

Your email address will not be published. Required fields are marked *

6 comments on “TWiV 952: Jake Scott put the ID in COVID-19

  1. Marge Nov 6, 2022

    Please add a link for the Spike T shirts.

  2. After the 14 minute mark as I listen Dr Scott goes on and on about no covid pneumonia. BS! Arn’t the stats hundreds of Covid fatalities per day? As I listen I hope you guys scure his butt.

  3. Stephen Ditmore Nov 10, 2022

    What surprises me is that you didn’t ask Dr. Scott who should be the next NIAID Director. My candidate is another West Coast infectious diseases MD, Dr. Monica Gandhi. What do Daniel & Sara think?

    I’d like to see MIT’s Michael B. Yaffe, who you’ve had on TWIV, made the next NIH Director.

    In response to Justin’s letter, check out:

  4. Paul Blanchard Nov 16, 2022

    Dr. Jake Scott’s perspective on Covid-19 was very informative and offered a differing take on the situation from Dr. Daniel Griffin. Both doctors have very good points to consider.
    With regard to Dr. Scott’s endorsement of Bebtilovimab as a first-line treatment, my personal experience is that in September, when I was seeking out this drug for a patient there was one dose available in a multi-county region and the pharmacy informed me they could now bill Medicare and the patient for the medication at an expected cost of $4,000 without any assurance it would be paid for by Medicare or supplemental insurance.
    This is in contrast to Paxlovid which does not have payment uncertainties yet. I fully understand that your podcast is science focused and not cost or economics focused, but the availability of the recommended drugs and its cost remain as major issues for the physicians and practitioners prescribing for Covid-19. Thanks.
    Paul Blanchard, MD,
    Petoskey, Michigan